{"id":"https://openalex.org/W775166252","doi":"https://doi.org/10.1182/blood.v124.21.990.990","title":"CC-486 (Oral Azacitidine) Following Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) in Patients with Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML)","display_name":"CC-486 (Oral Azacitidine) Following Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) in Patients with Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML)","publication_year":2014,"publication_date":"2014-12-06","ids":{"openalex":"https://openalex.org/W775166252","doi":"https://doi.org/10.1182/blood.v124.21.990.990","mag":"775166252"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v124.21.990.990","doi":"https://doi.org/10.1182/blood.v124.21.990.990","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v124.21.990.990","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5064150576","display_name":"Basem Magdy William","orcid":"https://orcid.org/0000-0001-8090-4605","observed_orcids":["https://orcid.org/0000-0001-8090-4605"]},"institutions":[{"id":"https://openalex.org/I4210119077","display_name":"University Hospitals Seidman Cancer Center","ror":"https://ror.org/02kb97560","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799343972","https://openalex.org/I4210119077"]},{"id":"https://openalex.org/I58956616","display_name":"Case Western Reserve University","ror":"https://ror.org/051fd9666","country_code":"US","type":"education","lineage":["https://openalex.org/I58956616"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Basem M. William","raw_affiliation_strings":["University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, OH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, OH","institution_ids":["https://openalex.org/I4210119077","https://openalex.org/I58956616"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034264716","display_name":"Marcos J. G. De Lima","orcid":"https://orcid.org/0000-0002-8568-4522","observed_orcids":["https://orcid.org/0000-0002-8568-4522"]},"institutions":[{"id":"https://openalex.org/I4210119077","display_name":"University Hospitals Seidman Cancer Center","ror":"https://ror.org/02kb97560","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799343972","https://openalex.org/I4210119077"]},{"id":"https://openalex.org/I58956616","display_name":"Case Western Reserve University","ror":"https://ror.org/051fd9666","country_code":"US","type":"education","lineage":["https://openalex.org/I58956616"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Marcos de Lima","raw_affiliation_strings":["University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, OH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, OH","institution_ids":["https://openalex.org/I4210119077","https://openalex.org/I58956616"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085076031","display_name":"Bet\u00fcl Oran","orcid":"https://orcid.org/0000-0003-1264-5968","observed_orcids":["https://orcid.org/0000-0003-1264-5968"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Betul Oran","raw_affiliation_strings":["The University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048913229","display_name":"Richard E. Champlin","orcid":"https://orcid.org/0000-0002-4314-5037","observed_orcids":["https://orcid.org/0000-0002-4314-5037"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Richard Champlin","raw_affiliation_strings":["MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058746837","display_name":"Esperanza Bouza Papadopoulos","orcid":"https://orcid.org/0000-0001-6066-1861","observed_orcids":["https://orcid.org/0000-0001-6066-1861"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Esperanza B Papadopoulos","raw_affiliation_strings":["Memorial Sloan-Kettering Cancer Center, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Memorial Sloan-Kettering Cancer Center, New York, NY","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070096873","display_name":"Sergio  A. Giralt","orcid":"https://orcid.org/0000-0003-1944-5053","observed_orcids":["https://orcid.org/0000-0003-1944-5053"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sergio Giralt","raw_affiliation_strings":["Memorial Sloan-Kettering Cancer Center, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Memorial Sloan-Kettering Cancer Center, New York, NY","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074629157","display_name":"Bart Lee Scott","orcid":"https://orcid.org/0000-0001-9620-7839","observed_orcids":["https://orcid.org/0000-0001-9620-7839"]},"institutions":[{"id":"https://openalex.org/I4210089486","display_name":"Fred Hutch Cancer Center","ror":"https://ror.org/007ps6h72","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210089486"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Bart L. Scott","raw_affiliation_strings":["Fred Hutchinson Cancer Research Center, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Fred Hutchinson Cancer Research Center, Seattle, WA","institution_ids":["https://openalex.org/I4210089486"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003299911","display_name":"Joel Hetzer","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387155837","display_name":"Celgene (United States)","ror":"https://ror.org/0527yg379","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4387155837"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Joel Hetzer","raw_affiliation_strings":["Celgene Corporation, Summit, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celgene Corporation, Summit, NJ","institution_ids":["https://openalex.org/I4387155837"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051615608","display_name":"Xiwei Wang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387155837","display_name":"Celgene (United States)","ror":"https://ror.org/0527yg379","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4387155837"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Xiwei Wang","raw_affiliation_strings":["Celgene Corporation, Summit, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celgene Corporation, Summit, NJ","institution_ids":["https://openalex.org/I4387155837"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052836154","display_name":"Eric J. Laille","orcid":"https://orcid.org/0000-0002-7823-0004","observed_orcids":["https://orcid.org/0000-0002-7823-0004"]},"institutions":[{"id":"https://openalex.org/I4387155837","display_name":"Celgene (United States)","ror":"https://ror.org/0527yg379","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4387155837"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Eric Laille","raw_affiliation_strings":["Celgene Corporation, Summit, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celgene Corporation, Summit, NJ","institution_ids":["https://openalex.org/I4387155837"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111658759","display_name":"Barry Skikne","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387155837","display_name":"Celgene (United States)","ror":"https://ror.org/0527yg379","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4387155837"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Barry S. Skikne","raw_affiliation_strings":["Celgene Corporation, Summit, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celgene Corporation, Summit, NJ","institution_ids":["https://openalex.org/I4387155837"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5076984999","display_name":"Charles Craddock","orcid":"https://orcid.org/0000-0001-5041-6678","observed_orcids":["https://orcid.org/0000-0001-5041-6678"]},"institutions":[{"id":"https://openalex.org/I2799307867","display_name":"Queen Elizabeth Hospital Birmingham","ror":"https://ror.org/048emj907","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1308923049","https://openalex.org/I2799307867"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Charles Craddock","raw_affiliation_strings":["Centre for Clinical Hematology, Queen Elizabeth Hospital, Birmingham, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Centre for Clinical Hematology, Queen Elizabeth Hospital, Birmingham, United Kingdom","institution_ids":["https://openalex.org/I2799307867"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":7,"corresponding_author_ids":["https://openalex.org/A5003299911","https://openalex.org/A5051615608","https://openalex.org/A5052836154"],"corresponding_institution_ids":["https://openalex.org/I4387155837"],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":4,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"124","issue":"21","first_page":"990","last_page":"990"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10345","display_name":"Hematopoietic Stem Cell Transplantation","score":0.8589000105857849,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10345","display_name":"Hematopoietic Stem Cell Transplantation","score":0.8589000105857849,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.13279999792575836,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11559","display_name":"Retinoids in leukemia and cellular processes","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/cc-486","display_name":"CC-486","score":0.906000018119812},{"id":"https://openalex.org/keywords/oral-azacitidine","display_name":"oral azacitidine","score":0.9700000286102295},{"id":"https://openalex.org/keywords/allogeneic-hematopoietic-stem-cell-transplantation","display_name":"allogeneic hematopoietic stem cell transplantation","score":0.921999990940094},{"id":"https://openalex.org/keywords/myelodysplastic-syndrome","display_name":"myelodysplastic syndrome","score":0.996999979019165},{"id":"https://openalex.org/keywords/acute-myeloid-leukemia","display_name":"acute myeloid leukemia","score":1.0},{"id":"https://openalex.org/keywords/maintenance-therapy","display_name":"maintenance therapy","score":0.8100000023841858},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.8159999847412109},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.9789999723434448},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9729999899864197},{"id":"https://openalex.org/keywords/graft-versus-leukemia-effect","display_name":"graft-versus-leukemia effect","score":0.7699999809265137},{"id":"https://openalex.org/keywords/graft-versus-host-disease","display_name":"graft-versus-host disease","score":0.9760000109672546},{"id":"https://openalex.org/keywords/epigenetic-therapy","display_name":"epigenetic therapy","score":0.6700000166893005},{"id":"https://openalex.org/keywords/hla-mismatched-donors","display_name":"HLA-mismatched donors","score":0.5830000042915344}],"concepts":[{"id":"https://openalex.org/C2776239401","wikidata":"https://www.wikidata.org/wiki/Q416451","display_name":"Azacitidine","level":5,"score":0.8245891332626343},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7603918313980103},{"id":"https://openalex.org/C2780817109","wikidata":"https://www.wikidata.org/wiki/Q954625","display_name":"Myelodysplastic syndromes","level":3,"score":0.6565019488334656},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5665806531906128},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.5588797926902771},{"id":"https://openalex.org/C2911091166","wikidata":"https://www.wikidata.org/wiki/Q106419912","display_name":"Transplantation","level":2,"score":0.5308882594108582},{"id":"https://openalex.org/C2780235182","wikidata":"https://www.wikidata.org/wiki/Q1181878","display_name":"Decitabine","level":5,"score":0.5218973755836487},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4854446053504944},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.4848543405532837},{"id":"https://openalex.org/C2777408962","wikidata":"https://www.wikidata.org/wiki/Q1128050","display_name":"Hematopoietic stem cell transplantation","level":3,"score":0.4626525342464447},{"id":"https://openalex.org/C2779972918","wikidata":"https://www.wikidata.org/wiki/Q1194520","display_name":"Graft-versus-host disease","level":3,"score":0.4574394226074219},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.43611469864845276},{"id":"https://openalex.org/C2779282312","wikidata":"https://www.wikidata.org/wiki/Q1956561","display_name":"Myeloid","level":2,"score":0.4334113597869873},{"id":"https://openalex.org/C2779823535","wikidata":"https://www.wikidata.org/wiki/Q6865356","display_name":"Minimal residual disease","level":3,"score":0.4120187759399414},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.35618484020233154},{"id":"https://openalex.org/C2780007613","wikidata":"https://www.wikidata.org/wiki/Q546523","display_name":"Bone marrow","level":2,"score":0.2368306815624237},{"id":"https://openalex.org/C190727270","wikidata":"https://www.wikidata.org/wiki/Q874745","display_name":"DNA methylation","level":4,"score":0.08025151491165161},{"id":"https://openalex.org/C150194340","wikidata":"https://www.wikidata.org/wiki/Q26972","display_name":"Gene expression","level":3,"score":0.0},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood.v124.21.990.990","doi":"https://doi.org/10.1182/blood.v124.21.990.990","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v124.21.990.990","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2469723064","https://openalex.org/W2944822648","https://openalex.org/W2808807711","https://openalex.org/W2884246240","https://openalex.org/W2555024572","https://openalex.org/W2593191135","https://openalex.org/W7204723125","https://openalex.org/W2535838980","https://openalex.org/W6995988910","https://openalex.org/W2562266793"],"abstract_inverted_index":{"Abstract":[0],"Background:":[1],"Disease":[2],"relapse":[3,41],"and":[4,24,44,47,68,148,180,210,220,251,258,312,315,339,366,398,407,447,478,492,541,556,558,564,573,586,599,615,665,677,690],"graft":[5,63,578],"vs":[6,64],"host":[7],"disease":[8],"(GvHD)":[9],"following":[10,153,591,606],"alloHSCT":[11,60,128,154,171],"are":[12,200,280,299,305,329],"major":[13],"causes":[14],"of":[15,29,73,86,103,122,151,260,310,318,334,483,603,627,651,685,694,700,718],"treatment":[16],"(Tx)":[17],"failure":[18],"in":[19,38,42,129,155,354,413,517,610,668,706],"patients":[20],"(pts)":[21],"with":[22,131,157,163,172,187,325,370,511,546,569,596,612,630],"MDS":[23,43,132,158,165,365],"AML":[25,45,167,369,616],"(Paietta,":[26],"2012).":[27,79],"Studies":[28],"parenteral":[30],"azacitidine,":[31],"an":[32],"epigenetic":[33],"modifier,":[34],"have":[35,169],"shown":[36],"efficacy":[37],"preventing":[39],"post-transplant":[40,670],"pts,":[46,440,524],"possibly":[48],"reducing":[49],"GvHD":[50,70,219,465,482,695],"severity":[51],"(Platzbecker,":[52],"2012;":[53],"de":[54,732],"Lima,":[55],"2010).":[56],"Azacitidine":[57],"maintenance":[58,125],"after":[59,127,212,320,474,496],"may":[61],"enhance":[62],"leukemia":[65],"(GvL)":[66],"effects":[67],"reduce":[69],"by":[71,683],"expansion":[72],"regulatory":[74],"T":[75],"cells":[76],"(Goodyear,":[77],"2010,":[78],"CC-486":[80,123,152,202,238,321,335,433,444,467,571,592,608,624,647,703],"is":[81,204,230,267,625,663],"a":[82,116,294,401,691,711,714],"novel":[83],"oral":[84,623],"formulation":[85],"azacitidine":[87,319,581,632,673],"which,":[88],"as":[89,91,124,710],"well":[90,666],"potentially":[92],"allowing":[93],"easier":[94],"administration":[95],"over":[96],"extended":[97,702],"schedules,":[98],"could":[99],"increase":[100],"the":[101,138,192,274,355,431,437,472,484,669,697],"duration":[102],"drug":[104],"exposure":[105],"to":[106,233,285,425,481,501,713],"residual":[107],"malignant":[108],"cells.":[109],"We":[110],"now":[111],"report":[112],"preliminary":[113,712],"results":[114],"from":[115,377,385,471,642],"prospective":[117],"phase":[118],"I/II":[119],"dose-finding":[120],"study":[121,473],"Tx":[126,203,217,263,277,288,336,434,445,468,498],"pts":[130,156,352,393,450,507,611],"or":[133,159,166,175,184,197,241,253,324,381,388,421,595,653],"AML.":[134,160],"Objective:":[135],"To":[136],"evaluate":[137,234],"maximum":[139],"tolerated":[140,667],"dose":[141],"(MTD),":[142],"dose-limiting":[143],"toxicities":[144],"(DLT),":[145],"pharmacokinetics":[146],"(PK),":[147],"safety":[149],"outcomes":[150],"Methods:":[161],"Pts":[162,214,304],"WHO-defined":[164],"who":[168,181,463],"undergone":[170],"myeloablative":[173],"(MAC)":[174],"reduced-intensity":[176],"conditioning":[177],"(RIC)":[178],"regimens":[179,572,705],"had":[182,362,368,394,400,451,464,539,553,561],"sibling":[183,389],"unrelated":[185,386],"donors":[186],"\u22641":[188],"antigen":[189,396],"mismatch":[190,397],"at":[191,457,634,649],"HLA-A,":[193],"-B,":[194],"-C,":[195],"-DRB1":[196],"-DQB1":[198],"locus,":[199],"enrolled.":[201],"initiated":[205],"between":[206],"days":[207,659],"(d)":[208],"42":[209],"84":[211],"alloHSCT.":[213],"receive":[215],"prophylactic":[216],"for":[218,246,290,307,350,419,489,535,622,657],"infections":[221],"per":[222],"institutional":[223],"standard.":[224],"A":[225],"standard":[226,326],"3x3":[227],"MTD":[228,265],"design":[229],"being":[231],"used":[232],"4":[235,441,661],"dosing":[236,704],"schedules:":[237],"200":[239,652],"mg":[240,243,655],"300":[242,654],"QD,":[244],"administered":[245,633,648],"7":[247,351,658],"d":[248,255,332],"(Cohorts":[249,256],"1":[250,333,338,360,395,486,493,551,559,724],"2)":[252],"14":[254],"3":[257,506],"4)":[259],"repeated":[261],"28d":[262],"cycles.":[264],"determination":[266],"based":[268],"on":[269,331],"DLT":[270,420,567,689],"that":[271,628,646],"occur":[272],"during":[273,430],"first":[275,356,432],"2":[276,287,357,415,448,519,536,728],"cycles":[278,289,337,446,455,499],"(pts":[279],"not":[281,417,452,681],"evaluable":[282,418,439],"if":[283],"unable":[284],"complete":[286],"reasons":[291],"other":[292],"than":[293],"DLT).":[295],"Adverse":[296],"events":[297],"(AEs)":[298],"graded":[300],"using":[301],"NCI-CTCAE":[302],"v4.0.":[303],"followed":[306],"safety,":[308],"incidence":[309],"acute":[311],"chronic":[313],"GvHD,":[314],"relapse.":[316,502],"PK":[317,422,587,678],"administration,":[322],"alone":[323,594],"concomitant":[327,597,686],"medications,":[328,598],"evaluated":[330],"2.":[340,730],"Results:":[341],"At":[342,503],"data":[343,347,458,504,641],"cut-off":[344,459],"(7/17/2014),":[345],"outcome":[346],"were":[348,527,533,544,589,600,680],"available":[349],"enrolled":[353],"cohorts":[358],"(Table):":[359],"pt":[361,412,462,487,494,516,575],"IPSS":[363],"Int-2":[364],"6":[367,438,454,497],"high-risk":[371],"features.":[372],"Stem":[373],"cell":[374],"source":[375],"was":[376,416],"bone":[378],"marrow":[379],"(n=2)":[380,390],"peripheral":[382],"blood":[383],"(n=5)":[384,387],"donors.":[391],"Two":[392],"5":[399],"full":[402],"match.Conditioning":[403],"included":[404],"MAC":[405],"(n=3)":[406],"RIC":[408],"(n=4)":[409],"regimens.":[410],"One":[411,461],"Cohort":[414,518],"assessments":[423],"due":[424,500],"early":[426],"discontinuation":[427],"(AML":[428],"relapse)":[429],"cycle.":[435],"Of":[436],"completed":[442],"\u22656":[443],"ongoing":[449,698,708],"reached":[453],"on-study":[456],"(Table).":[460,514],"before":[466],"subsequently":[469],"withdrew":[470,488],"developing":[475],"febrile":[476,562],"neutropenia":[477,563],"diarrhea":[479],"related":[480],"bowel;":[485],"personal":[490],"reasons;":[491],"discontinued":[495],"cut-off,":[505],"remained":[508],"on-study,":[509],"all":[510,523],"continued":[512],"CR":[513],"No":[515,566,688],"developed":[520],"GvHD.":[521],"For":[522],"most":[525],"AEs":[526,532],"grade":[528],"1-2.":[529],"Grade":[530],"3-4":[531],"reported":[534],"pts:":[537],"both":[538],"nausea":[540],"vomiting,":[542],"which":[543],"controlled":[545],"antiemetic":[547],"agents":[548],"upon":[549],"onset;":[550],"also":[552,560],"device-related":[554],"infection":[555],"dyspnea,":[557],"rash.":[565],"emerged":[568],"these":[570],"no":[574],"experienced":[576],"secondary":[577],"failure.":[579],"Overall":[580],"plasma":[582,674],"concentration":[583,675],"profiles":[584,676],"(Figure)":[585],"parameters":[588,679],"similar":[590,607],"given":[593],"within":[601],"range":[602,621],"values":[604],"observed":[605],"doses":[609,650],"MDS,":[613],"CMML,":[614],"(Garcia-Manero,":[617,637],"2011).":[618,638],"The":[619],"AUC":[620],"~10%":[626],"seen":[629],"subcutaneous":[631],"75":[635],"mg/m2":[636],"Conclusion:":[639],"Preliminary":[640],"this":[643,707,719],"analysis":[644],"suggest":[645],"QD":[656],"every":[660],"weeks":[662],"safe":[664],"setting.":[671],"Overall,":[672],"affected":[682],"use":[684],"medications.":[687],"low":[692],"rate":[693],"support":[696],"evaluation":[699],"14d":[701],"study,":[709],"prospective,":[715],"randomized":[716],"trial":[717],"new":[720],"agent":[721],"post-transplant.":[722],"Figure":[723,725,727,729],"1.":[726],"Disclosures":[731],"Lima:":[733],"Celgene:":[734],"Consultancy.":[735,737],"Champlin:Celgene:":[736],"Giralt:Celgene:":[738],"Consultancy,":[739,746],"Honoraria,":[740,747,767],"Research":[741,748,768],"Funding,":[742],"Speakers":[743],"Bureau.":[744],"Scott:Celgene:":[745],"Funding.":[749,769],"Hetzer:Celgene:":[750],"Employment,":[751,755,759,763],"Equity":[752,756,760,764],"Ownership.":[753,757,761,765],"Wang:Celgene:":[754],"Laille:Celgene:":[758],"Skikne:Celgene:":[762],"Craddock:Celgene:":[766]},"counts_by_year":[{"year":2016,"cited_by_count":2},{"year":2015,"cited_by_count":2}],"updated_date":"2026-10-30T12:39:25.321706","created_date":"2016-06-24T00:00:00"}